Cargando…
Development and Structural Analysis of Antibody Therapeutics for Filoviruses
The filoviruses, including ebolaviruses and marburgviruses, are among the world’s deadliest pathogens. As the only surface-exposed protein on mature virions, their glycoprotein GP is the focus of current therapeutic monoclonal antibody discovery efforts. With recent technological developments, poten...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949092/ https://www.ncbi.nlm.nih.gov/pubmed/35335698 http://dx.doi.org/10.3390/pathogens11030374 |
_version_ | 1784674811958525952 |
---|---|
author | Yu, Xiaoying Saphire, Erica Ollmann |
author_facet | Yu, Xiaoying Saphire, Erica Ollmann |
author_sort | Yu, Xiaoying |
collection | PubMed |
description | The filoviruses, including ebolaviruses and marburgviruses, are among the world’s deadliest pathogens. As the only surface-exposed protein on mature virions, their glycoprotein GP is the focus of current therapeutic monoclonal antibody discovery efforts. With recent technological developments, potent antibodies have been identified from immunized animals and human survivors of virus infections and have been characterized functionally and structurally. Structural insight into how the most successful antibodies target GP further guides vaccine development. Here we review the recent developments in the identification and characterization of neutralizing antibodies and cocktail immunotherapies. |
format | Online Article Text |
id | pubmed-8949092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89490922022-03-26 Development and Structural Analysis of Antibody Therapeutics for Filoviruses Yu, Xiaoying Saphire, Erica Ollmann Pathogens Review The filoviruses, including ebolaviruses and marburgviruses, are among the world’s deadliest pathogens. As the only surface-exposed protein on mature virions, their glycoprotein GP is the focus of current therapeutic monoclonal antibody discovery efforts. With recent technological developments, potent antibodies have been identified from immunized animals and human survivors of virus infections and have been characterized functionally and structurally. Structural insight into how the most successful antibodies target GP further guides vaccine development. Here we review the recent developments in the identification and characterization of neutralizing antibodies and cocktail immunotherapies. MDPI 2022-03-18 /pmc/articles/PMC8949092/ /pubmed/35335698 http://dx.doi.org/10.3390/pathogens11030374 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Yu, Xiaoying Saphire, Erica Ollmann Development and Structural Analysis of Antibody Therapeutics for Filoviruses |
title | Development and Structural Analysis of Antibody Therapeutics for Filoviruses |
title_full | Development and Structural Analysis of Antibody Therapeutics for Filoviruses |
title_fullStr | Development and Structural Analysis of Antibody Therapeutics for Filoviruses |
title_full_unstemmed | Development and Structural Analysis of Antibody Therapeutics for Filoviruses |
title_short | Development and Structural Analysis of Antibody Therapeutics for Filoviruses |
title_sort | development and structural analysis of antibody therapeutics for filoviruses |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949092/ https://www.ncbi.nlm.nih.gov/pubmed/35335698 http://dx.doi.org/10.3390/pathogens11030374 |
work_keys_str_mv | AT yuxiaoying developmentandstructuralanalysisofantibodytherapeuticsforfiloviruses AT saphireericaollmann developmentandstructuralanalysisofantibodytherapeuticsforfiloviruses |